{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113410","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.146016+00:00","generated_at":"2026-06-09T01:58:07.431746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Innoviva Q3 2023: GSK royalties $57M, net income $82M, launches XACDURO, positive Phase 3 zoliflodacin","bullets":["GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.","Net income $82.0M ($1.26 basic EPS) vs $265.5M ($3.81) in Q3 2022; prior year included gain on sale.","Launched XACDURO for Acinetobacter HABP/VABP; announced positive Phase 3 zoliflodacin for gonorrhea.","Appointed Stephen Basso as CFO; repurchased $11.0M of stock in Q3.","Cash $180.0M; invested $25M in Armata Pharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113410","json":"https://secwatch.observer/filing/0001104659-23-113410.json","markdown":"https://secwatch.observer/filing/0001104659-23-113410.md","text":"https://secwatch.observer/filing/0001104659-23-113410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/0001104659-23-113410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/tm2329306d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:58:07.431746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cc4e72fef34caa30be6603c26ca22b20d13f787","claim":"Innoviva, Inc. reported the third quarter ended September 30, 2023 results: net income $82.0 million, EPS $1.26 basic per share.","evidence_excerpt":"On November 1, 2023, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/0001104659-23-113410-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$82.0 million"},{"label":"EPS","value":"$1.26 basic per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}